Overview

A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma

Status:
Active, not recruiting

Trial end date:
2022-08-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the efficacy and safety of tislelizumab as second line treatment in participants with advanced unresectable/metastatic ESCC that has progressed during or after first line therapy.

Phase:

Phase 3

Details

Lead Sponsor:

BeiGene

Treatments:

Albumin-Bound Paclitaxel
Camptothecin
Docetaxel
Irinotecan
Paclitaxel